Speakers Title & Biography
|
|
- Hubert Francis
- 5 years ago
- Views:
Transcription
1 Speakers Title & Biography Dr. Janice M. Soreth Deputy Director, FDA Europe Office/CDER, Liaison to EMA Dr. Soreth 20-year agency veteran with unparalleled experience, including serving as CDER's director of the division of Anti-Infectives and Ophthalmology as well as working in CBER and the Office of Combination Products/Office of the Commissioner. Dr. Soreth is FDA CDER liaison based with EMEA. Having an FDA presence in Europe greatly facilitates and enhances the large body of work on which FDA currently collaborates with its European counterpart agencies. The EMEA is one of FDA s closest regulatory partners in the area Dr. Theresa M. Finn Assoc. Director for Regulatory Policy, Office of Vaccines Research and Review, CBER, FDA Dr. Theresa Finn is the Associate Director for Regulatory Policy in the Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER), FDA. Theresa received her B.A and Ph.D from Trinity College Dublin, Ireland. After postdoctoral positions in Bern, Switzerland and Boston, Massachusetts she joined CBER in 1990 as a Visiting Scientist in the Laboratory of Pertussis, OVRR. In 1999, she took a full time regulatory position in the Division of Vaccine and Related Product Applications, OVRR. She has over 20 years of vaccine regulatory experience. This experience includes serving as reviewer on numerous INDs, and as chair and reviewer on a number of vaccine license applications and supplements. She has represented FDA and OVRR on several working groups and committees. 1 P a g e
2 Dr. Anthony Newcombe Dr. Anthony Newcombe, Principal Consultant, at PAREXEL Consulting, is a PhD Biochemist who draws on 15 years of experience providing operational & manufacturing support for late stage development activities, including process transfer, scale up and validation of biopharmaceutical production processes. Dr. Newcombe has expertise supporting the development and validation of a broad range of biologics including vaccines, antibodies and recombinant proteins and has managed pre-qualification (design space) studies in accordance with the FDA's QbD pilot regulatory submission program. Dr. Newcombe utilizes his industrial experience to provide process validation strategies and policies to support enhanced or traditional approaches to biopharmaceutical development and process validation. Prior to joining PAREXEL, Dr. Newcombe held senior leadership positions within industry as Head of Process & Product Validation, Global Industrial Operations, GlaxoSmithKline Biologicals and as a member of the Technical Leadership Team at Pfizer Biotechnology Ireland. He was responsible for developing global validation strategies for biopharmaceutical development through global implementation with a strategy of challenging industry standard practices to improve speed and efficiency of process validation. Dr. Newcombe holds a PhD in Biochemistry from the MRC National Institute for Medical Research, London and undertook postdoctoral studies to evaluate anticancer therapeutics at the Marie Curie research Institute, Surrey UK. Dr. Newcombe is a frequent speaker at industry forums, is a Fellow of the Royal Society of Chemistry (FRSC) and certified Chartered Chemist (CChem), has been a member of the PDA CMC Vaccines and ISPE working groups and is a member of the Editorial Board, Journal of Protein Expression and Purification. 2 P a g e
3 Dr. Vann Parker Vann Parker, Principal Consultant, at PAREXEL Consulting, during 25 years in the industry has been a team leader for products in all stages of development from discovery research and pre-ind stages, through market applications and post-approval support. Dr. Parker has worked in a broad range of therapeutic areas including Oncology, Neurology, Metabolism, Infectious Diseases, Inflammation and Cardiovascular, primarily focused on clinical and program management aspects. Dr. Parker provides strategic support for clients in the generation of product development plans and in preparation for Regulatory Agency review meetings. He has represented clients as their US Agent for interactions with the FDA, providing guidance and advice for timing and content of submissions. Dr. Parker has helped clients with other important aspects of development such as Orphan Drug Designation, Pediatric Investigational Plans, REMS submissions, and product labeling. At PAREXEL he has coordinated project teams to facilitate the integration of PAREXEL and client expertise. Prior to joining PAREXEL, Dr. Parker worked at Ribozyme Pharmaceuticals where he helped the company file its first IND and build a Development group. He was team leader for the program, coordinating efforts with corporate development partners. Dr. Parker began his career at Amgen, where he held various positions in Research and Development over fifteen years, including Clinical Research Project Team Leader. Dr. Parker has a PhD in Molecular Biology from Caltech and a BS in Chemistry and Biology from Duke University. His publications include papers on receptor-ligand interactions and clinical research. 3 P a g e
4 Dr. Partha Roy Dr. Partha Roy, Principal Consultant, at PAREXEL Consulting, has over 13 years of pharmaceutical R&D experience both in industry and US FDA with proven expertise in Clinical Pharmacology and Regulatory Sciences across multiple therapeutic areas (pulmonary, cough/cold/allergy, rheumatology and GI) encompassing both small molecules and biologics. Dr. Roy recently joined PAREXEL Consulting as a Principal Consultant providing strategic guidance on various clinical and regulatory aspects of drug development. His primary areas of expertise include Biosimilars and Biologics, Inhalation and Nasal drug products, Pediatric and Formulation development and OTC medications. As a FDA reviewer/team leader, Dr. Roy had extensive review experience dealing with issues around 505(b)(2) pathway, BA/BE, dose selection, PK and PK/PD, biomarkers, clinical trial design, drug-drug interactions, special populations, pediatric plan and labeling. Dr. Roy utilizes his experience to negotiate drug development plans with review divisions at FDA and develop regulatory strategies with clients for a favorable outcome. He is currently helping multiple clients mapping out regulatory strategies for drug candidates ranging from pre-ind to NDA stages, each one facing significant development challenges. Dr. Roy also frequently leads and coordinates FDA submissions (PIND, IND, NDA, postmarketing) for clients. Dr. Roy holds a PhD in Biochemical Toxicology from the College of Public Health, University of South Florida, a B.S. in Pharmacy from Jadavpur University, India, and has completed a postdoctoral training in Drug Metabolism and Pharmacokinetics at Boston University. Dr. Roy is a frequent speaker at national and international meetings and has authored several peer-reviewed articles including invited reviews. 4 P a g e
5 Mr. Joakim Steen Mikkelsen, M.Sc. Health Care & Lifesciences Attaché, Royal Danish Embassy, Washington D.C. Mr. Mikkelsen leads the Danish Foreign Ministry and Trade Councils Medical and Lifesciences efforts in the United States, providing regulatory, policy and market access guidance for the medical and pharmaceutical industry. Prior to joining the Embassy, Mr. Mikkelsen was part of the management team at CMC Biopharmaceuticals, a CMO for protein-based biopharmaceuticals. At CMC, he served as Business Development and Sales Director and assisted with obtaining and expanding its European Manufacturing Authorization. Further, Mr. Mikkelsen has obtained several certificates at the Medical Faculty of Copenhagen University within Human Care and Medicine, as well as followed executive pharmaceutical and biotech programs at the Wharton School, PA and at Rutgers Business School, NJ. Finally, Mr. Mikkelsen has completed Certificate Programs for International Regulatory Authorities, with the FDA CDRH and FDA CDER. Mr. Mikkelsen holds an international M.Sc. degree in Management of Technology from Copenhagen Business School and Rouen Graduate School of Management in France. 5 P a g e
CONTRACT RESEARCH SERVICES
1537 NW 65th Avenue Plantation, FL 33313 USA Phone: (954) 321-8988 Fax: (954) 321-9778 info@receptopharm.com www.receptopharm.com ReceptoPharm has installed the pathways to develop, produce and supply
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationCareer Growth Areas in Physiology / Pharmacology
Career Growth Areas in Physiology / Pharmacology Magdalena Alonso-Galicia, PhD Pharmacology Department Forest Research Institute, Inc. Jersey City, NJ 1 Career Growth Areas in BioPharma n Pharmaceutical
More informationAntibody Discovery at Evotec
Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic
More informationFood and Drug Administration (FDA) 101
Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the
More informationSenior Regulatory Affairs Executive AREAS OF EXPERTISE
Senior Regulatory Affairs Executive AREAS OF EXPERTISE More than fifteen years experience in vaccines, pharmaceuticals, biotechnology, and combination device products. Experience in regulatory strategy
More informationNIH-RAID: A ROADMAP Program
NIH-RAID: A ROADMAP Program (Rapid Access to Interventional Development} A Program designed to facilitate the development of new therapeutics The NIH-RAID Pilot Program is intended to reduce some of the
More informationAddressing challenges in Drug Development and Quality Control with innovative solutions
Addressing challenges in Drug Development and Quality Control with innovative solutions SYNOPSIS 16 May 2013, 9:30 am 3:00 pm Gd. Titan Centre (Theater Room) This seminar is designed for scientists in
More informationEARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS
EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS As a full service contract research organisation performing phase I to IV clinical trials across Europe and the Americas for 40
More informationPRELIMINARY AGENDA ** Attendees must already be registered to attend cphi Japan conference**
PRELIMINARY AGENDA ** Attendees must already be registered to attend cphi Japan conference** The Future of Biologics Development and Manufacturing 20 April 2017 13:00 16:00 Big Sight Exhibition Center,
More informationASMS Workshop Report
ASMS Workshop Report 1.Title of workshop and those presiding Title: Get Ready to Become an MS Rising Star -Young Mass Spectrometrists Workshop Presided by Olga Friese (Pfizer) and Dian Su (Genentech) 2.Date
More informationSHORT COURSE. Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SUNDAY, SEPTEMBER 17
SHORT COURSE SUNDAY, SEPTEMBER 17 OMNI PROVIDENCE HOTEL PROVIDENCE, RI Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SPONSORED BY: Organized by: www.bostonsociety.org
More informationEXPERT COLLECTION. Explore our leading medical review series
EXPERT COLLECTION Explore our leading medical review series Introducing the EXPERT COLLECTION The Taylor & Francis Expert Collection is the world s largest series of review journals in research, development,
More informationIntroduction to Drug Design and Discovery
Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,
More informationFrom Bench To Clinic : a personal journey Career Research Advancement Focused Training
From Bench To Clinic : a personal journey Career Research Advancement Focused Training February 13, 2018 Irina Tcherepanova Ph.D. Vice President of Translational Medicine Argos Therapeutics Inc. FDA view
More informationAgreed with W. Cornell Graduate Program and Tri-I
Drug Development Course From Molecule to Prescription Weill Cornell Graduate School - Tri-Institutional Therapeutics Discovery Institute ABOUT THIS COURSE This course has been designed in collaboration
More informationIntroduction of Development Center for Biotechnology TAIWAN
Introduction of Development Center for Biotechnology TAIWAN DCB Nonprofit Organization Founded in 1984 Funded Mainly by Ministry of Economic Affairs (MOEA), National Science Council and the Industry 394
More informationUNLEASH THE POWER OF PRECISION MEDICINE
FROM BENCH TO BEDSIDE UNLEASH THE POWER OF PRECISION MEDICINE DCB, pioneer in biotech. Your partner in drug discovery. www.dcb.org.tw The Center for Biotechnology With over 400 dedicated researchers and
More informationFrom Bench to Bedside. Russ H. Read June 23, 2014
From Bench to Bedside Russ H. Read June 23, 2014 Talent Required Scientists, clinicians, technicians, chemists, biologists, pharmacologists, toxicologists, research associates, regulatory experts, manufacturing
More informationDrug-Device Combination Product Development: INDs for Device Companies
Drug-Device Combination Product Development: INDs for Device Companies David Armbruster Global Program Manager April 24, 2013 Drug-Device Combination Product Development -or- The scenic route to an IND
More informationNonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016
Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies Whitney S. Helms, PhD IOM, February 29,2016 Disclaimer The views disseminated in this talk are my own and do not necessarily represent
More informationCAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS
CAREER DEVELOPMENT FOR EXPERIENCED REGULATORY PROFESSIONALS How TOPRA can support you as you drive your regulatory career forward ABOUT TOPRA TOPRA (The Organisation for Professionals in Regulatory Affairs)
More informationibio, Inc. Holds Annual Meeting in College Station, Texas
April 7, 2016 ibio, Inc. Holds Annual Meeting in College Station, Texas NEW YORK, NY -- (Marketwired) -- 04/07/16 -- ibio, Inc. (NYSE MKT: IBIO) - Speaking to shareholders at the ibio, Inc. (NYSE MKT:
More informationCMC Strategy Forum Japan November Piyanan Boonprasirt Bureau of Drug Control Thailand Food and Drug Administration
CMC Strategy Forum Japan 2015 9-10 November 2015 Piyanan Boonprasirt Bureau of Drug Control Thailand Food and Drug Administration 1 1. Background 2. Organization Chart 3. Biological Products 4. Regulation
More informationCERTIFICATE IN BIOPHARMACEUTICALS
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034-2713 Phone: 267.468.8560 Fax: 267.468.8565 CERTIFICATE IN BIOPHARMACEUTICALS and GENERIC DRUGS Temple offers
More informationComparative Study of Regulatory Requirements for Biologics Filing in United States and European Union
Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction
More informationIndia as an Outsourcing Frontier in Biotechnology
1 India as an Outsourcing Frontier in Biotechnology K.V. Subramaniam President & CEO 3 rd Annual Biotech Supply Chain Academy Conference San Francisco Oct 26, 2010 Biotechnology Industry Issues Long gestation
More informationMark D. Kramer, RAC Regulatory Strategies, Inc.
Mark D. Kramer, RAC Regulatory Strategies, Inc. 808 E. Fox Lane Fox Point, Wisconsin 53217 (414) 731-4257 kramer@regulatorystrategies.net Experience Regulatory Strategies, Inc. Fox Point, Wisconsin President,
More informationEnvigo Corporate & Industry Overview. Rutgers University
Envigo Corporate & Industry Overview Rutgers University Joseph Bedford, Ph.D. Corporate Vice President, Strategic Marketing November 15, 2016 envigo.com 1 Who we are Envigo is a global contract research
More informationDr. Earl Dye CMC/GMP Considerations for Expedited Development Programs
Dr. Earl Dye CMC/GMP Considerations for Expedited Development Programs Earl Dye is Director of Technical Regulatory Policy in Genentech s Washington, DC Regulatory Affairs Office, and is the FDA Liaison
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationCorporate. Established in Acquired facilities of: Competencies across the Generics & Biologics, value chain.
Established in 2013 Acquired facilities of: Corporate Enzon Pharmaceuticals- NJ, USA- 2013 Pfizer- NY, USA- 2016 Competencies across the Generics & Biologics, value chain. Contract Manufacturing Fully
More informationKFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar
KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar Kyung-Min Baek, Ph.D. Recombinant Protein Products Division Korea Food and Drug Administration(KFDA) Biopharmaceuticals A biopharmaceutical
More informationSPEED UP YOUR TIME TO MARKET
SPEED UP YOUR TIME TO MARKET #Pre-clinical #Biologics #Small molecules Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies
More informationMay 23, :30 PM-5:00 PM - AUDITORIUM A250. May 9, :30 PM -5:00 PM - AUDITORIUM A-950 May 16, :30 PM-5:00 PM - AUDITORIUM A250
DRUG DEVELOPMENT COURSE - FROM MOLECULE TO PRESCRIPTION WEILL CORNELL GRADUATE SCHOOL - TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE THURSDAYS FROM 3:00PM - 5:00PM AT 1300 YORK AVE, NEW YORK, N.Y.
More informationSchool of Pharmacy TEMPLE UNIVERSITY
School of Pharmacy TEMPLE UNIVERSITY Regulatory Affairs and Quality Assurance Graduate Program Te mple Unive rsity School of Pharmacy Re gulatory Affairs and Quality Assurance Graduate Program 4 25 Comme
More informationTRIANNI Media Kit MEDIA CONTACT CORPORATE HEADQUARTERS. Trianni, Inc. San Francisco, CA
TRIANNI Media Kit CORPORATE HEADQUARTERS Trianni, Inc. San Francisco, CA Telephone: 1.866.374.9314 MEDIA CONTACT Mandy Boyd Director of Marketing @Trianni_mAb Website: Trianni.com TECHNOLOGY LEADERSHIP
More informationCompeting & Collaborating to Achieve Successful Drug Repositioning
Competing & Collaborating to Achieve Successful Drug Repositioning Noel Southall, Ph.D. National Human Genome Research Institute National Institutes of Health July 14, 2011 NIH Chemical Genomics Center
More informationGlobal Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box.
Global Allied Pharmaceuticals, LLC. Innovation, Research, and Technology. Breaking the bounders, first in its class, thinking outside the box. The purpose of this presentation Looking for Joint Venture
More informationDrug Development & the FDA Pharmacy 309 November 2005
Goals & Objectives Drug Development & the FDA Pharmacy 309 November 2005 Tom Hazlet, Pharm.D., Dr.P.H. H375S 206.616.2732 thazlet@u... Be able to describe major regulatory events in the drug & biologic,
More informationAT A GLANCE. inventivhealthclinical.com
AT A GLANCE inventivhealthclinical.com 1 Table of Contents OVERVIEW 02 PHASE I-IIA 03 PHASE IIB-III 04 LATE STAGE 05 STRATEGIC RESOURCING 06 BIOANALYTICAL 07 QUALITY ASSURANCE 08 CONSULTING 09 THERAPEUTIC
More informationYour bridge to. better medicines
Your bridge to better medicines At a Glance Anapharm Bioanalytics is a client-oriented, GLP-certified, FDA-inspected, GCP-compliant and ANVISA-certified bioanalytical contract research organization (CRO)
More informationA Life-cycle Approach to Dose Finding Studies
A Life-cycle Approach to Dose Finding Studies Rajeshwari Sridhara, Ph.D. Director, Division of Biometrics V Center for Drug Evaluation and Research, USFDA This presentation reflects the views of the author
More informationMaster List of Professional Electives Course Title Description Credit Hours. Note: This class only meets for the last 7 class periods of the semester.
Course Number PHTH7044 PHRX7064 PHRX704C PHRX706 PHTH8048 PHRX 904 PHRX 904 Master List of Professional Electives Course Title Description Credit Hours Advanced Cardiac Life Support Emphasis (P only) Advanced
More informationFUTURE MEANS CREATIVITY
START-UP & ACADEMICS THEORY & PRACTICE IN DRUG DEVELOPMENT 1 EARLY PHASE DRUG DEVELOPMENT COURSE MAY 9 TH 2017 - ANTWERP FUTURE MEANS CREATIVITY VENUE: LINDNER HOTEL LANGE KIEVITSTRAAT 125 BE-2018 ANTWERP,
More informationPharmaceutical Toxicology: Toxicology in the Nonclinical Development of Drugs and Biologics. December 3-4, 2012 PERI Training Facility ~ Arlington, VA
Pharmceutical Toxicology: Tentative Agenda Pharmaceutical Toxicology: Toxicology in the Nonclinical Development of Drugs and Biologics December 3-4, 2012 PERI Training Facility ~ Arlington, VA Monday,
More informationCenter for Drug Evaluation and Research. CDER Small Business and Industry Assistance. (CDER SBIA) and New Drug Review.
Center for Drug Evaluation and Research Small Business and Industry Assistance (CDER SBIA) and New Drug Review LT Renu Lal, Pharm.D. CDER Small Business and Industry Assistance Division of Drug Information
More informationFDA Guidance, Clinical Pharmacology, and Regulatory Science
Principles of Clinical Pharmacology NIH, April 25, 2013 FDA Guidance, Clinical Pharmacology, and Regulatory Science Carl Peck, MD UCSF Center for Drug Development Science Washington DC and San Francisco
More informationYour partner for successful biopharmaceutical development and approval
Your partner for successful biopharmaceutical development and approval About the Founders Experienced experts with unique agency and industry backgrounds Dr. Gabriele Dallmann + 25 years of experience
More informationNIPTE RESEARCH CONFERENCE
NIPTE RESEARCH CONFERENCE Critical Path Research for Pharmaceutical Process Scale-Up and Stability June 15-16, 2011 Conference Center Building 2 The Universities at Shady Grove 9630 Gudelsky Drive Rockville,
More informationIs a Career in the. Pharmaceutical. Check out our online Student Center to find out more:
Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aaps.org/forstudents How Do I Know If a Career in the Pharmaceutical Sciences is Right
More informationExecutive Search. Chief Standards Officer
Executive Search Chief Standards Officer Client Overview Sterling Martin Associates has been retained by the Clinical Data Interchange Standards Consortium (CDISC) to search for Chief Standards Officer
More informationImpurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA
Overview of exploratory INDs Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA July, 15 16, 2008 David Jacobson-Kram, Ph.D. DABT Office of New Drugs Center for Drug Evaluation
More informationDennis Wright, Ph.D. Professor of Medicinal Chemistry NPDD Initiative UCONN School of Pharmacy University of Connecticut
Craig M. Crews, Ph.D. Lewis B. Cullman Professor of Molecular, Cellular, and Developmental Biology Chemistry, Pharmacology Center for Molecular Discovery Yale University Dennis Wright, Ph.D. Professor
More informationInnovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing
Innovative Pharmaceutical Solutions for Discovery Chemistry, Biology and cgmp Manufacturing Overview Serving biotech and pharma community since 1998 Proven track record of advancing small molecules from
More informationRole of the FDA and PDUFA in Drug Development
Role of the FDA and PDUFA in Drug Development Questions to be addressed 1. What is the Food and Drug Administration and why is it important? 2. Why was the Prescription Drug User Fee Act (PDUFA) created?
More informationHow to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER
How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco
More informationB.Sc., Biology, California State University at Hayward Ph.D., Cell Biology, University of California at Los Angeles
Cecil Pickett President, Research & Development B.Sc., Biology, California State University at Hayward Ph.D., Cell Biology, University of California at Los Angeles Dr. Pickett joined Biogen Idec in 2006.
More informationMissouri Regional Life Sciences Summit March 9, 2010 The Institute for Advancing Medical Innovation Stepping into the future of drug discovery, delivery and biomedical engineering G. Sitta Sittampalam,
More informationINVESTIGATIONS BOOTCAMP NIBRT (NATIONAL INSTITUTE FOR BIO-PROCESSING RESEARCH AND TRAINING)
INVESTIGATIONS BOOTCAMP IN PARTNERSHIP WITH NIBRT (NATIONAL INSTITUTE FOR BIO-PROCESSING RESEARCH AND TRAINING) Dates: January 29 th - 31 st, 2013 Time: 8:30am-5:30pm Venue: NIBRT, Dublin Training Outline
More informationOncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges
The content of this presentation reflects the opinion of the speaker and does not necessarily represent the official position of CDER Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory
More informationPost-Baccalaureate Program in Pharmaceutical Science. Accelerate your career
Post-Baccalaureate Program in Pharmaceutical Science Accelerate your career pharmsci.uci.edu pharmsci-grad@uci.edu 949.824.1991 Improve your career options The Post-Baccalaureate Program in Pharmaceutical
More informationBaek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety
Baek, Kyung-min Recombinant Protein Products Division Ministry of Food and Drug Safety About Ministry of Food and Drug Safety Regulation for Biosimilar Principle of Biosimilar Approach Status of Biosimilar
More informationReflections on a career in Pharmaceutical Statistical Sciences: My Journey. James R. Johnson, PhD (UD04)
Reflections on a career in Pharmaceutical Statistical Sciences: My Journey James R. Johnson, PhD (UD04) 1 My Journey 7 Different Pharmaceutical Companies 30 years (1983 to 2013) Retired to Consulting and
More informationWorkshop: Flight Simulator: Learning How to Develop Complex Generic Drug Products
Workshop: Flight Simulator: Learning How to Develop Complex Generic Drug Products The availability of generic drug products can mitigate the risk of drug shortages, help make prescription drugs more affordable,
More informationPharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA
Pharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA 1 2 ND MENA Regulatory Conference On Bioequivalence, Biowaivers, Bioanalysis, Dissolution & Biosimilars
More informationModern Approaches to Process Understanding
Biomanufacturing and Process Development (BPD) Modern Approaches to Process Understanding Thursday, September 18, 2014 1:00 pm - Registration begins 1:15 5:00 pm - Presentations & Networking North Carolina
More informationPediatric Assessment in Drug Development and Regulatory Approval in Japan
Pediatric Assessment in Drug Development and Regulatory Approval in Japan Mayumi SHIKANO, Ph.D. Associate Director, Center for Product Evaluation Pharmaceuticals and Medical Devices Agency 2016/3/8 1 Disclaimer
More information3M Drug Delivery Systems. April 26, 2011
3M MDI Manufacturing April 26, 2011 3M Drug Delivery Systems Drug Delivery Systems Overview 3M Drug Delivery Systems is a division of 3M that is dedicated to the development and manufacturing of inhalation
More information1. Clinical Program Manager (ideally based in greater Boston, MA, USA area)
Livzon Mabpharm, Inc ( 珠海丽珠单抗生物技术有限公司 ) a development stage biotech company, was jointly founded by two publically traded companies (Livzon Pharmaceuticals Group and JointCare). It focuses on the development,
More informationList of E-journals Subscribed for the year 2016 (January to December) Pharmacy Faculty Sl. No.
Faculty 1 Adolescent Psychiatry Psychiatry 2 Anti Cancer Agents in Medicinal / Pharma & Quality 3 Anti-Infective Agents Pharmaceutical Microbiology 4 Anti-Inflammatory & Anti- Allergy Agents in Medicinal
More informationLife Sciences. Key issues for senior life sciences executives. Pharmaceutical patents in Canada: key issues for life sciences companies
Life Sciences 2017 Key issues for senior life sciences executives Pharmaceutical patents in Canada: key issues for life sciences companies Yoon Kang and Daphne Lainson Smart & Biggar/Fetherstonhaugh Innovative
More informationCATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity
CATEGORY Advertising Guidance Agenda: New & Guidances CDER is Planning to Publish During Calendar Year 2016 (See the Good Guidance Practices (GGPs) regulation on this Web page or 21 CFR 10.115 for details
More informationIndustry Perspective: The Challenges and Benefits in using Expedited Regulatory Pathways
Industry Perspective: The Challenges and Benefits in using Expedited Regulatory Pathways Alan Poirier, Pfizer Inc. U.S. Regulatory Policy and Global Intelligence Worldwide Safety and Regulatory American
More informationDrugs, medical progress,
Drugs, medical progress, and the road ahead Scott Gottlieb, MD Resident Fellow The American Enterprise Institute Page 1 The Pharmaceutical Industry s Market Global Pharmaceutical Sales, by Region (in billions
More informationAmerican Association of Pharmaceutical Scientists (AAPS)
American Association of Pharmaceutical Scientists (AAPS) AAPS, King Street, Alexandria, VA, USA* he American Association of Pharmaceu- Scientists (AAPS), founded in 1986, Ttical is an individual membership
More informationRegulatory Perspectives on Gene Therapies for Rare Diseases Rare Diseases Forum Washington, D.C. October 17, 2018
Regulatory Perspectives on Gene Therapies for Rare Diseases Rare Diseases Forum Washington, D.C. October 17, 2018 Rachel Witten, M.D. Medical Officer Office of Tissues and Advanced Therapies Center for
More informationSpeed your time to market with FDA s expedited programs
Regulatory Sciences Expediting drug approval Speed your time to market with FDA s expedited programs The faster way to marketing submission and drug approval for serious conditions and rare diseases In
More informationRole of Academic Investigators in Drug Development
DTRCS Regulatory Education Seminar, June 12, 2007 Role of Academic Investigators in Drug Development Howard Lee, MD, PhD Associate Adjunct Professor Director, Center for Drug Terminology Sponsor Investigator
More informationADAPTIVE PATHWAYS WORKSHOP
ADAPTIVE PATHWAYS WORKSHOP Stockholm Friday, November 10, 2017 9:00 13:00 Adaptive Pathways Applications for Scientific Insights in Europe PRESENTED BY: An ICON plc Company Agenda Overview 9:00 9:10 9:10
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More information2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges Thursday, May 9 Registration Open Continental Breakfast
2019 PDA Biosimilars and Vaccines Conference: Lifecycle Similarities and Challenges End-to-End Product Development Manufacturing, Supply, and Quality May 9-10, 2019 Hilton Long Beach Long Beach, CA As
More informationGlobal Clinical Trials in Korea
Global Clinical Trials in Korea In-Sook Park Department of Drug Evaluation Korea Food & Drug Administration Contents Regulatory changes relevant to Clinical Trials in Korea Current Status of Clinical Trials
More informationA drug development crossroad lies ahead
G L O B A L C B O C O S T E F F E C T I V E B I O A N A L Y T I C A L H I G H Q U A L I T Y E A R L Y S T A G E C L I N I C A L T R A N S L A T I O N A L M E D I C I N E H I G H L Y C O M P E T E N T A
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationPATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT. For personal use only
PATHWAY TO VALUE CREATION NASDAQ: BNTC ASX: BLT Annual General Meeting Presentation 8 November 2018 Jerel A. Banks, M.D., Ph.D. Chief Executive Officer and Executive Chairman SAFE HARBOR STATEMENT This
More informationRegulations of Biologics in Taiwan
Regulations of Biologics in Taiwan Churn-Shiouh Gau, Ph.D. Executive Director, Taiwan 2013/2/13 1 Outlines Regulation of Drugs in Taiwan - Organizations Regulations for Marketing Approval for Drugs including
More informationThe Role of Chemists in the FDA Drug Approval Process
The Role of Chemists in the FDA Drug Approval Process 231 st ACS National Meeting Atlanta, GA M. Scott Furness, Ph.D. March 26, 2006 Introduction Presentation Outline FDA Organization CDER Organization
More informationEARLY PHASE DEVELOPMENT SOLUTIONS
EARLY PHASE DEVELOPMENT SOLUTIONS Real-world case studies demonstrating accelerated timelines, risk reduction and measurable cost savings are possible Early Phase Development Solutions is a unique drug
More informationConducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development
Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development 2015 AAPS Annual Meeting and Exposition October 28, 2015 Kimberly Raines, Ph.D. Lead Pharmacologist Quality
More informationDate/Lecturer Class Topic Readings 01/28/10 Brookman
Course Director: Sheldon, Ph.D. 01/28/10 1 I. Course Description and Requirements II. Historical Perspectives and Overview of Drug Development a. Evolution of the pharmaceutical industry b. Changing development
More informationAccelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective
Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Imran M. Khan, Ph.D. Division of Psychiatry Center for Drug Evaluation and Research FDA
More informationCDER 2016 Actions and 2017 Priorities. Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA
CDER 2016 Actions and 2017 Priorities Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA Disclosure My comments today are mine and do not necessarily represent the views of the US
More informationJob Title: Head, Clinical Science Job Location: Nanjing, China CV to: Wechat:
Job Title: Head, Clinical Science Job Description: As a senior member of the Clinical Development organization, the Head of Clinical Science will supervise a team of staff to lead the clinical development
More informationHUMAN CHALLENGE TESTING
HUMAN CHALLENGE TESTING CLINICAL RESEARCH SOLUTIONS DE-RISKING Faced with increasing pressures on timelines and budgets, clinical research practices need to continuously evolve in order to ensure pipeline
More informationSharmila et al. International Journal of Drug Regulatory Affairs; 2017, 5(1), ISSN: Available online at
REGULATORY REQUIREMENTS OF SIMILAR BIOLOGICS FOR MARKETING AUTHORIZATION IN INDIA Available online at www.ijdra.com REVIEW ARTICLE Sharmila Reddy V*, Mounica N.V.N., Anusha S, Evangeline L, Nagabhushanam
More informationNavigating through the Clinical Trial Authorization Process in Russia
Navigating through the Clinical Trial Authorization Process in Russia Clinical Endpoint ANDA Program Optimization White Paper Series Aramayis Kocharyan, Pharm.D, LLM Vladimir Petrov, Ph.D. Introduction
More information4.3 Qualification Expertise (Canada)
L1 4.3 Qualification Expertise (Canada) Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical Trials
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationCOMBINATION PRODUCTS Inspection Readiness and Outcomes
WHITE PAPER COMBINATION PRODUCTS Inspection Readiness and Outcomes Many companies think that because they have a good relationship with the FDA Center they interacted with during their submission reviews
More information